Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal Allogeneic CD19/BCMA CAR T-cells in Relapsed/Refractory Autoimmune Diseases
NCT06978738Phase 1Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in systemic lupus erythematosus (SLE), autoimmune hemolytic anemia (AIHA), myasthenia gravis (MG) and 4 more, sponsored by Changzhou Second People's Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 90 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
systemic lupus erythematosus (SLE)autoimmune hemolytic anemia (AIHA)myasthenia gravis (MG)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06978738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978738.